Comparative Evaluation of Enzalutamide and Apalutamide in the Management of Prostate Cancer: A Comprehensive Review
Comparative Evaluation of Enzalutamide and Apalutamide in the Management of Prostate Cancer: A Comprehensive Review
Prostate cancer is a prevalent malignancy among men, with androgen receptor (AR) signaling playing a critical role in its progression. The AR is a transcriptional factor for testosterone and dihydrotestosterone and consists of four main domains: the N-terminal domain, DNA-binding domain, hinge region, and ligand-binding domain [1].
Androgen signaling is pivotal in both the development and maintenance of the prostate. It regulates gene transcriptional processes through AR nuclear translocation, binding to androgen response elements on target genes, and recruitment of or crosstalk with transcription factors [2]. Targeting the AR pathway is a primary intervention for managing prostate cancer.
Introduction to Androgen Receptor Antagonists: Therapeutic strategies targeting AR have emerged, including androgen synthesis inhibitor-abiraterone and androgen receptor antagonists like enzalutamide and apalutamide. These drugs have shown significant improvement in survival rates among prostate cancer patients [3].
Mechanism of Action
Enzalutamide Mechanism and Binding Affinity: Enzalutamide, a second-generation nonsteroidal AR antagonist, exhibits strong binding affinity to AR. It operates as a competitive AR inhibitor, thwarting androgen binding to its receptor, AR nuclear translocation, and subsequent interaction with chromosomal DNA, thereby inhibiting the androgen signaling pathway without significant AR agonist activity [4].
Apalutamide Mechanism and Binding Affinity: Similar to enzalutamide, apalutamide inhibits nuclear translocation of the androgen-AR complex and its binding with DNA. Apalutamide binds to the same ligand-binding site as bicalutamide, but with a 7- to 10-fold increased affinity for AR. It selectively binds to the ligand-binding domain of AR, blocking AR nuclear translocation or binding to androgen response elements [5].
Pharmacokinetics and Pharmacodynamics
Absorption, Distribution, Metabolism, and Excretion (ADME) of Enzalutamide: The detailed ADME profile of enzalutamide is not covered in the sources accessed, hence it's recommended to consult primary literature or drug monographs for comprehensive information.
ADME of Apalutamide: The detailed ADME profile of apalutamide also remains uncovered in the accessed sources, recommending a similar approach of consulting primary literature or drug monographs for in-depth information.
Clinical Efficacy
The AFFIRM, PREVAIL, and PROSPER trials were significant studies that assessed the efficacy of Enzalutamide in different stages of prostate cancer. In these trials, over 800 patients were included in the Enzalutamide arm, showcasing a broad spectrum of patient demographics with a median age of approximately 70 years [6].
The PROSPER trial met its primary endpoint of metastasis-free survival (MFS), marking a notable reduction in the risk of developing metastasis or death with Enzalutamide plus ADT compared to ADT alone in men with non-metastatic castration-resistant prostate cancer (nmCRPC) [7].
The SPARTAN trial, a phase III study, evaluated Apalutamide versus placebo in patients with nmCRPC. This trial was conducted at 332 sites in 26 countries, embodying a global perspective on the drug's efficacy [8].
<!-- -->
- The TITAN trial, another pivotal phase III study, revealed that Apalutamide significantly improved overall survival and radiographic progression-free survival in patients with metastatic castration-sensitive prostate cancer (mCSPC) receiving ongoing androgen deprivation therapy (ADT) [9].
Direct Comparative Studies
Comparative analyses indicate no significant differences in efficacy between Enzalutamide and Apalutamide. In a real-world trial, both drugs performed comparably, although Apalutamide resulted in a more significant early reduction in prostate-specific antigen (PSA) from baseline of 90% or more in patients with mCSPC [10].
A network meta-analysis presented at the 2021 ASCO Genitourinary Cancers Symposium revealed comparable performances between Enzalutamide and Apalutamide concerning metastasis-free survival and time to PSA progression, based on data from the pivotal trials PROSPER, SPARTAN, and ARAMIS. This meta-analysis provided an indirect comparison in the absence of head-to-head trial data, showing no significant differences between the two drugs in managing non-metastatic castration-resistant prostate cancer.
Safety and Tolerability
Common Adverse Events: Enzalutamide and apalutamide, as second-generation androgen receptor inhibitors (ARIs), have been associated with several adverse events (AEs) in patients with non-metastatic castration-resistant prostate cancer (nmCRPC). Common AEs include fatigue, falls, fractures, and rash [11]. Additional adverse effects of enzalutamide are hot flush, hypertension, diarrhea, upper respiratory tract infection, and decreased weight.
Serious Adverse Events: Serious side effects of apalutamide may include seizures, osteoporosis, falls, bone fractures, severe cutaneous adverse events, embryo-fetal toxicity, and cardiovascular events [12].
Patient Tolerability: Both agents have shown efficacy in the treatment of nmCRPC, however, darolutamide appears to have a more favorable tolerability profile in comparison to enzalutamide and apalutamide, especially regarding fatigue and cognitive deficits [13].
Management of Adverse Events: Management strategies for AEs induced by enzalutamide or apalutamide include AE-directed treatment (38.0%), ARI discontinuation (10.4%), dose reduction (7.6%), and AE-related hospitalization (4.8%) [11].
Resistance Mechanisms
Known Resistance Mechanisms to Enzalutamide: Resistance to enzalutamide can arise from multiple mechanisms including AR amplification, point mutations, expression of AR splice variants which are ligand independent, intratumoral androgen production or downstream signaling mechanisms, and potentially a mutation conferring agonistic properties to both enzalutamide and apalutamide [14].
Known Resistance Mechanisms to Apalutamide: Similar to enzalutamide, resistance mechanisms for apalutamide include AR amplification, point mutations, and the expression of ligand-independent AR splice variants. Apalutamide and darolutamide share similar resistant mechanisms with enzalutamide and abiraterone, involving the AKR1C3/AR-V7 complex which confers cross-resistance to second-generation androgen receptor-targeted therapies in advanced prostate cancer [15].
Quality of Life and Patient Preference
Both enzalutamide and apalutamide have shown efficacy in the management of prostate cancer, but they come with distinct side effect profiles which might impact the quality of life (QoL) of patients. Apalutamide was associated with more instances of hypothyroidism, rash, falls, and fractures, making it possibly less suitable for patients with pre-existing thyroid disorders or a history of osteopenia or osteoporosis [16].
On the other hand, enzalutamide was linked with a higher chance of hypertension, which could be a consideration for some patient populations.
A study titled "Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study" revealed the health-related QoL post apalutamide treatment, although specifics were not detailed in the snippet.
Conclusion
The side effect profiles of enzalutamide and apalutamide play a crucial role in determining patient and clinician preference. While both drugs have shown efficacy, the individual side effects and the patient populations they best serve can significantly impact quality of life and treatment choices.
Understanding the differential side effect profiles and the patient populations that may benefit more from one drug over the other is crucial for personalized medicine in prostate cancer management. This knowledge will help clinicians make more informed decisions to enhance patient care and possibly improve the quality of life for their patients.
Bibliography
[1]: Fujita K, Nonomura N. Role of Androgen Receptor in Prostate Cancer: A Review. World J Mens Health. 2019 Sep;37(3):288-295. doi: 10.5534/wjmh.180040. Epub 2018 Sep 10. PMID: 30209899; PMCID: PMC6704300. (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6704300/)
[2]: Lonergan PE, Tindall DJ. Androgen receptor signaling in prostate cancer development and progression. J Carcinog. 2011;10:20. doi: 10.4103/1477-3163.83937. Epub 2011 Aug 23. PMID: 21886458; PMCID: PMC3162670. (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162670/)
[3]: Jacob, A.; Raj, R.; Allison, D.B.; Myint, Z.W. Androgen Receptor Signaling in Prostate Cancer and Therapeutic Strategies. Cancers 2021, 13, 5417. (https://www.mdpi.com/2072-6694/13/21/5417)
[4]: Rajaram P, Rivera A, Muthima K, Olveda N, Muchalski H, Chen QH. Second-Generation Androgen Receptor Antagonists as Hormonal Therapeutics for Three Forms of Prostate Cancer. Molecules. 2020 May 24;25(10):2448. doi: 10.3390/molecules25102448. PMID: 32456317; PMCID: PMC7287767. (https://pubmed.ncbi.nlm.nih.gov/32456317/)
[5]: Li, Tammy. "Comparison of Second-Generation Antiandrogens for the Treatment of Prostate Cancer." The Journal of Hematology Oncology Pharmacy, 2021, (https://jhoponline.com/issue-archive/2022-issues/april-2022-vol-12-no-2/19338-comparison-of-second-generation-antiandrogens-for-the-treatment-of-prostate-cancer)
[6]: Tombal B, Stenzl A, Cella D, Loriot Y, Armstrong AJ, Fizazi K, Beer T, Sternberg CN, Hussain M, Ivanescu C, Ganguli A, Ramaswamy K, Saad F. The Impact of Enzalutamide on the Prostate Cancer Patient Experience: A Summary Review of Health-Related Quality of Life across Pivotal Clinical Trials. Cancers (Basel). 2021 Nov 23;13(23):5872. doi: 10.3390/cancers13235872. PMID: 34884981; PMCID: PMC8657254. (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8657254/)
[7]: "Final PROSPER Results Show XTANDI® (Enzalutamide) Significantly Extends Overall Survival in Men with Non-Metastatic Castration-Resistant Prostate Cancer | Pfizer." Pfizer.com, 2020, (https://www.pfizer.com/news/press-release/press-release-detail/final-prosper-results-show-xtandir-enzalutamide)
[8]: "Final Survival Results from SPARTAN, a Phase III Study of Apalutamide (APA) versus Placebo (PBO) in Patients (Pts) with Nonmetastatic Castration-Resistant Prostate Cancer (NmCRPC). | Journal of Clinical Oncology." Journal of Clinical Oncology, 2020, (https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.5516)
[9]: "Final Analysis Results from TITAN: A Phase III Study of Apalutamide (APA) versus Placebo (PBO) in Patients (Pts) with Metastatic Castration-Sensitive Prostate Cancer (MCSPC) Receiving Androgen Deprivation Therapy (ADT). | Journal of Clinical Oncology." Journal of Clinical Oncology, 2021, ascopubs.org/doi/abs/10.1200/JCO.2021.39.6_suppl.11. (https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.6_suppl.11)
[10]: Doherty, Kyle. "Apalutamide Yields Earlier Reduction in PSA vs Enzalutamide in MCSPC." Cancer Network, Cancer Network, 17 Feb. 2022, (https://www.cancernetwork.com/view/apalutamide-yields-higher-benefit-vs-enzalutamide-in-mcspc)
[11]: Hussain, Arif, et al. "Real-World Burden of Adverse Events for Apalutamide- or Enzalutamide-Treated Non-Metastatic Castration-Resistant Prostate Cancer Patients in the United States." BMC Cancer, vol. 22, no. 1, BioMed Central, Mar. 2022, https://doi.org/10.1186/s12885-022-09364-z. (https://bmccancer.biomedcentral.com/articles/10.1186/s12885-022-09364-z)
[12]: "Apalutamide." Nih.gov, National Institute of Diabetes and Digestive and Kidney Diseases, 15 Mar. 2023, (https://www.ncbi.nlm.nih.gov/books/NBK547950/)
[13]: Mori K, Mostafaei H, Pradere B, Motlagh RS, Quhal F, Laukhtina E, Schuettfort VM, Abufaraj M, Karakiewicz PI, Kimura T, Egawa S, Shariat SF. Apalutamide, enzalutamide, and darolutamide for non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis. Int J Clin Oncol. 2020 Nov;25(11):1892-1900. doi: 10.1007/s10147-020-01777-9. Epub 2020 Sep 14. PMID: 32924096; PMCID: PMC7572325. (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7572325/)
[14]: Rice, Meghan A., et al. "Second-Generation Antiandrogens: From Discovery to Standard of Care in Castration Resistant Prostate Cancer." Frontiers in Oncology, vol. 9, Frontiers Media, Aug. 2019, https://doi.org/10.3389/fonc.2019.00801. (https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2019.00801/full)
[15]: Zhao J, Ning S, Lou W, Yang JC, Armstrong CM, Lombard AP, D'Abronzo LS, Evans CP, Gao AC, Liu C. Cross-Resistance Among Next-Generation Antiandrogen Drugs Through the AKR1C3/AR-V7 Axis in Advanced Prostate Cancer. Mol Cancer Ther. 2020 Aug;19(8):1708-1718. doi: 10.1158/1535-7163.MCT-20-0015. Epub 2020 May 19. PMID: 32430485; PMCID: PMC8855880. (https://pubmed.ncbi.nlm.nih.gov/32430485/)
[16]: "Considerations for Apalutamide versus Enzalutamide in Prostate Cancer Treatment." Pharmacy Times, Pharmacy Times, 9 Apr. 2019, (https://www.pharmacytimes.com/view/considerations-for-apalutamide-versus-enzalutamide-in-prostate-cancer-treatment)